The antisense oligonucleotides market offers growth opportunities across diverse disease indications, with promising ...
Partnership combines Secarna’s OligoCreator® platform with VERAXA’s technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseasesZURICH, SWITZERLAND, and ...
In this Teach Me in 10, Dr. Cody Palumbo, a Senior Application Scientist in Technical Design at TriLink BioTechnologies, discusses why gRNA purity matters and how advanced purification solutions can ...
The phosphoramidites market shows promising growth in oligonucleotide synthesis, key to gene therapy and personalized ...
Agilent introduces the Altura Line of Inert HPLC Columns for superior results in biotherapeutic testing: Santa Clara, California Wednesday, October 1, 2025, 09:00 Hrs [IST] Agilen ...
iconPCR is transforming PCR assay development. DOE research that at one point required dozens of plates and long hours at the ...
CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to ...
Dublin-based Aerska, a biotechnology company specialising in the treatment of neurological diseases, announced its launch along with $21M (approximately ...
THX Pharma is entering a new strategic phase focused on regulatory approval, early access, and international commercialization of its medicines. Lyon, France - September 29 ...
Clinical Trials Arena on MSN

PepGen’s stock up 120% on DM1 trial success

PepGen’s stock has risen by over 120% after its investigational myotonic DM1 candidate reported the highest mean splicing ...